Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jul 21 2025

Full Issue

Viewpoints: GOP Using Flawed Report To Attack FDA; Preventative Care May Be RFK Jr.'s Next Target

Opinion writers discuss these public health issues.

For decades, the Food and Drug Administration has partnered with clinicians and industry to deliver evidence-based medical innovations using a gold-standard framework for drug development and oversight. The agency has the authority to review any approved drug, and such reviews are a vital part of ensuring public health. That process has long been grounded in transparent and methodologically sound science. (Grace Colon, 7/19)

The move by HHS comes in the wake of the Supreme Court’s June 27 decision in Kennedy v. Braidwood Management Inc., in which the justices ruled against a group of Christian-owned businesses and individuals challenging the constitutionality of the task force’s role in mandating what private insurance policies cover. (Karen Tumulty, 7/18)

Kennedy, who has no training in medicine or health, has long been the nation’s foremost peddler of junk science and the crackpot conspiracy theories that flow from it. The greatest danger in elevating him to HHS secretary was always that he would use his position to undermine public confidence in vaccines, which would lead to needless suffering and even death. And so it has come to pass. (Michael R. Bloomberg, 7/21)

My mother died in January 2007. She told the family that she had breast cancer in 2002. We still don’t know when she knew, or when she had been diagnosed. One thing we did know: She chose not to treat the cancer. (Joy Lisi Rankin, 7/21)

Sometime next year, my wife and I will look for a new health insurance plan. She is retiring early, and we won’t have access to the plans offered by her employer. Thanks to President Donald Trump and Republicans in Congress, our replacement likely will not be from the Colorado individual health insurance marketplace. (Mario Nicolais, 7/20)

They say death is one of life’s few certainties. For a boy or young man living with Duchenne muscular dystrophy, that certainty has a cruel twist: the anticipation of dying young. As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we never asked to join — said goodbye to their sons, the babies they once held in their arms, whose dreams they held in their hearts until Duchenne robbed them of working muscles or a healthy future. (Jennifer Handt and Kelly Maynard, 7/18)

From gene therapies to cancer breakthroughs, California has been the driving force behind America’s biotechnology industry. But today, that edge is slipping. A National Security Commission on Emerging Biotechnology report to Congress in April stated that the U.S. is dangerously close to falling behind China in biotechnology innovation, and called for urgent investment and strategic coordination to maintain global leadership. (Ash Jogalekar, 7/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ